CA2557791C - Controlled-release pharmaceutical composition and method for producing the same - Google Patents
Controlled-release pharmaceutical composition and method for producing the same Download PDFInfo
- Publication number
- CA2557791C CA2557791C CA2557791A CA2557791A CA2557791C CA 2557791 C CA2557791 C CA 2557791C CA 2557791 A CA2557791 A CA 2557791A CA 2557791 A CA2557791 A CA 2557791A CA 2557791 C CA2557791 C CA 2557791C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutical composition
- release
- controlled
- coating
- release pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004093506 | 2004-03-26 | ||
JP2004-093506 | 2004-03-26 | ||
PCT/JP2005/005217 WO2005092336A1 (ja) | 2004-03-26 | 2005-03-23 | 溶出制御製剤とその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2557791A1 CA2557791A1 (en) | 2005-10-06 |
CA2557791C true CA2557791C (en) | 2011-03-08 |
Family
ID=35055974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2557791A Expired - Fee Related CA2557791C (en) | 2004-03-26 | 2005-03-23 | Controlled-release pharmaceutical composition and method for producing the same |
Country Status (17)
Country | Link |
---|---|
US (2) | US20080095839A1 (pt) |
EP (1) | EP1728512A1 (pt) |
JP (1) | JPWO2005092336A1 (pt) |
KR (1) | KR100794078B1 (pt) |
CN (1) | CN1938026A (pt) |
AU (1) | AU2005225283B2 (pt) |
BR (1) | BRPI0509135A (pt) |
CA (1) | CA2557791C (pt) |
IL (1) | IL177087A (pt) |
MX (1) | MXPA06010785A (pt) |
MY (1) | MY139427A (pt) |
NO (1) | NO20064874L (pt) |
NZ (1) | NZ549838A (pt) |
RU (1) | RU2337687C2 (pt) |
TW (1) | TW200602085A (pt) |
WO (1) | WO2005092336A1 (pt) |
ZA (1) | ZA200607603B (pt) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
NZ549838A (en) * | 2004-03-26 | 2010-04-30 | Eisai R&D Man Co Ltd | Coated controlled-release preparation containing a gastric acid secretion inhibitor |
US20090208579A1 (en) * | 2004-12-27 | 2009-08-20 | Eisai R & D Management Co., Ltd. | Matrix Type Sustained-Release Preparation Containing Basic Drug or Salt Thereof, and Method for Manufacturing the Same |
US8481565B2 (en) | 2004-12-27 | 2013-07-09 | Eisai R&D Management Co., Ltd. | Method for stabilizing anti-dementia drug |
US20090148519A1 (en) * | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
EP1872778A1 (en) * | 2006-06-29 | 2008-01-02 | LEK Pharmaceuticals D.D. | Stable pharmaceutical composition with rabeprazole sodium |
DE102006035549A1 (de) | 2006-07-27 | 2008-01-31 | Evonik Röhm Gmbh | Arzneiform mit mindestens zweischichtiger Trennschicht |
WO2008015530A2 (en) * | 2006-08-03 | 2008-02-07 | Aurobindo Pharma Limited | Stable solid oral formulation of pantoprazole |
US20100105738A1 (en) * | 2006-10-06 | 2010-04-29 | Mitsuru Mizuno | Extended release formulations of a proton pump inhibitor |
AU2008286914B2 (en) | 2007-08-13 | 2014-10-02 | Ohemo Life Sciences Inc. | Abuse resistant drugs, method of use and method of making |
JP2009191034A (ja) * | 2008-02-15 | 2009-08-27 | Ss Pharmaceut Co Ltd | 時限放出製剤 |
JP4864024B2 (ja) * | 2008-02-15 | 2012-01-25 | エスエス製薬株式会社 | 時限放出製剤 |
JP2009191036A (ja) * | 2008-02-15 | 2009-08-27 | Ss Pharmaceut Co Ltd | 時限放出製剤 |
EP2255794A1 (en) * | 2009-05-29 | 2010-12-01 | H e x a l Aktiengesellschaft | Enteric coating |
JP5503192B2 (ja) * | 2009-06-03 | 2014-05-28 | 大原薬品工業株式会社 | 生理活性物質含有粒子の製造方法 |
BR112012002093A2 (pt) * | 2009-07-30 | 2017-09-12 | Evonik Roehm Gmbh | Composição compreendendo um material polimérico aniônico e o sal de um ácido monocarboxílico saturado tendo 6 a 22 átomos de carbono |
US8962020B2 (en) * | 2012-07-26 | 2015-02-24 | Glycadia Inc. | Long-acting and controlled release formulations of 2-[(3-chlorophenyl) amino] phenylacetic acid |
JP2014122328A (ja) * | 2012-11-22 | 2014-07-03 | Shin Etsu Chem Co Ltd | 押出成形機又は射出成形機洗浄用組成物及び押出成形機又は射出成形機の洗浄方法 |
EP2976082A4 (en) * | 2013-03-15 | 2016-05-11 | Inspirion Delivery Technologies Llc | MISS-INFANT COMPOSITIONS AND METHODS OF USE |
CN103976972B (zh) * | 2014-05-26 | 2017-09-12 | 中国药科大学 | 酒石酸唑吡坦口服脉冲控释给药系统及其制备方法 |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
ES2944568T3 (es) | 2015-07-17 | 2023-06-22 | Be Pharbel Mfg | Micropartículas multicapa de liberación de compuestos farmacéuticamente activos en forma de dosificación líquida |
EP3117824A1 (en) | 2015-07-17 | 2017-01-18 | BE Pharbel Manufacturing | Multilayered pharmaceutically active compound-releasing microparticles in a liquid dosage form |
CN105796532B (zh) * | 2016-03-28 | 2018-12-21 | 中国医药集团总公司四川抗菌素工业研究所 | 一种雷贝拉唑钠缓释胶囊及其制备方法 |
JP7472116B2 (ja) * | 2018-11-19 | 2024-04-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 耐アルコール性製剤 |
KR20210071242A (ko) * | 2019-12-06 | 2021-06-16 | 진양제약주식회사 | 제약 조성물 |
CN113069428B (zh) * | 2021-04-02 | 2023-02-10 | 珠海润都制药股份有限公司 | 一种雷贝拉唑钠肠溶片的制备方法 |
KR102647279B1 (ko) | 2021-04-08 | 2024-03-18 | 대한뉴팜(주) | 라베프라졸의 우수한 방출 특성을 갖는 라베프라졸 나트륨 및 산화마그네슘을 포함하는 제제 및 이의 제조방법 |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2336218C3 (de) * | 1973-07-17 | 1985-11-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh, 7750 Konstanz | Orale Arzneiform |
FR2471186A1 (fr) * | 1979-12-10 | 1981-06-19 | Roussel Uclaf | Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation |
JPS5846019A (ja) * | 1981-09-14 | 1983-03-17 | Kanebo Ltd | 持続性ニフエジピン製剤 |
US4863744A (en) * | 1984-09-17 | 1989-09-05 | Alza Corporation | Intestine drug delivery |
US4892742A (en) * | 1985-11-18 | 1990-01-09 | Hoffmann-La Roche Inc. | Controlled release compositions with zero order release |
JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
DE3822095A1 (de) * | 1988-06-30 | 1990-01-04 | Klinge Co Chem Pharm Fab | Neue arzneimittelformulierung sowie verfahren zu deren herstellung |
US5229131A (en) * | 1990-02-05 | 1993-07-20 | University Of Michigan | Pulsatile drug delivery system |
KR930006431B1 (ko) * | 1990-10-11 | 1993-07-16 | 재단법인 한국화학연구소 | 약물의 미세캡슐화 방법 |
YU48263B (sh) * | 1991-06-17 | 1997-09-30 | Byk Gulden Lomberg Chemische Fabrik Gmbh. | Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola |
US5260068A (en) * | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
FR2692146B1 (fr) * | 1992-06-16 | 1995-06-02 | Ethypharm Sa | Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention. |
US5260069A (en) * | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
EP0807433A4 (en) * | 1994-12-27 | 2005-12-28 | Akzo Nobel Nv | PREPARING WITH DELAYED RELEASE |
US5567441A (en) * | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
ES2137862B1 (es) * | 1997-07-31 | 2000-09-16 | Intexim S A | Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion. |
US6296876B1 (en) * | 1997-10-06 | 2001-10-02 | Isa Odidi | Pharmaceutical formulations for acid labile substances |
SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
US6328994B1 (en) * | 1998-05-18 | 2001-12-11 | Takeda Chemical Industries, Ltd. | Orally disintegrable tablets |
JP2000128779A (ja) * | 1998-10-20 | 2000-05-09 | Mitsui Chemicals Inc | 薬物放出制御型製剤 |
SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
US6183766B1 (en) * | 1999-02-12 | 2001-02-06 | The Procter & Gamble Company | Skin sanitizing compositions |
US6174902B1 (en) * | 1999-04-28 | 2001-01-16 | Sepracor Inc. | R-rabeprazole compositions and methods |
JP2001055322A (ja) * | 1999-08-18 | 2001-02-27 | Tanabe Seiyaku Co Ltd | パルス放出型製剤 |
US6369087B1 (en) * | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
ATE369857T1 (de) * | 1999-10-20 | 2007-09-15 | Eisai R&D Man Co Ltd | Methode zur stabilisierung von benzimidazol- verbindungen |
US6627223B2 (en) * | 2000-02-11 | 2003-09-30 | Eurand Pharmaceuticals Ltd. | Timed pulsatile drug delivery systems |
US20020045184A1 (en) * | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
KR20050044545A (ko) * | 2001-11-21 | 2005-05-12 | 에자이 가부시키가이샤 | 산에 불안정한 생리활성 화합물을 함유하는 제제 조성물및 그 제법 |
US20050163846A1 (en) * | 2001-11-21 | 2005-07-28 | Eisai Co., Ltd. | Preparation composition containing acid-unstable physiologically active compound, and process for producing same |
ATE329582T1 (de) * | 2002-04-29 | 2006-07-15 | Egyt Gyogyszervegyeszeti Gyar | Herstellung von tabletten von pharmazeutisch aktiven substanzen mit ungünstigen tablettierungseigenschaften mit einer mikrokristalline zellulose enthaltenden granulierflüssigkeit |
MXPA06009991A (es) * | 2004-03-03 | 2007-04-10 | Teva Pharma | Una composicion farmaceutica estable que comprende un farmaco labil acido. |
NZ549838A (en) * | 2004-03-26 | 2010-04-30 | Eisai R&D Man Co Ltd | Coated controlled-release preparation containing a gastric acid secretion inhibitor |
US20090148519A1 (en) * | 2005-09-29 | 2009-06-11 | Yasuhiro Zaima | Pulsed-release preparation having improved disintegration properties in vivo |
-
2005
- 2005-03-23 NZ NZ549838A patent/NZ549838A/en unknown
- 2005-03-23 CA CA2557791A patent/CA2557791C/en not_active Expired - Fee Related
- 2005-03-23 US US10/594,436 patent/US20080095839A1/en not_active Abandoned
- 2005-03-23 MY MYPI20051259A patent/MY139427A/en unknown
- 2005-03-23 KR KR1020067019778A patent/KR100794078B1/ko not_active IP Right Cessation
- 2005-03-23 AU AU2005225283A patent/AU2005225283B2/en not_active Ceased
- 2005-03-23 EP EP05727021A patent/EP1728512A1/en not_active Withdrawn
- 2005-03-23 WO PCT/JP2005/005217 patent/WO2005092336A1/ja active Application Filing
- 2005-03-23 BR BRPI0509135-7A patent/BRPI0509135A/pt not_active IP Right Cessation
- 2005-03-23 MX MXPA06010785A patent/MXPA06010785A/es active IP Right Grant
- 2005-03-23 RU RU2006134052/15A patent/RU2337687C2/ru not_active IP Right Cessation
- 2005-03-23 CN CNA2005800098028A patent/CN1938026A/zh active Pending
- 2005-03-23 JP JP2006511471A patent/JPWO2005092336A1/ja active Pending
- 2005-03-24 TW TW094109169A patent/TW200602085A/zh unknown
-
2006
- 2006-07-25 IL IL177087A patent/IL177087A/en not_active IP Right Cessation
- 2006-09-11 ZA ZA200607603A patent/ZA200607603B/en unknown
- 2006-10-06 US US11/543,991 patent/US20120003311A9/en not_active Abandoned
- 2006-10-26 NO NO20064874A patent/NO20064874L/no not_active Application Discontinuation
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8461187B2 (en) | 2004-06-16 | 2013-06-11 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
US9238029B2 (en) | 2004-06-16 | 2016-01-19 | Takeda Pharmaceuticals U.S.A., Inc. | Multiple PPI dosage form |
Also Published As
Publication number | Publication date |
---|---|
BRPI0509135A (pt) | 2007-08-28 |
EP1728512A1 (en) | 2006-12-06 |
AU2005225283B2 (en) | 2008-09-18 |
AU2005225283A1 (en) | 2005-10-06 |
RU2006134052A (ru) | 2008-04-10 |
RU2337687C2 (ru) | 2008-11-10 |
KR20060134124A (ko) | 2006-12-27 |
JPWO2005092336A1 (ja) | 2008-02-07 |
KR100794078B1 (ko) | 2008-01-10 |
MY139427A (en) | 2009-09-30 |
US20080095839A1 (en) | 2008-04-24 |
CN1938026A (zh) | 2007-03-28 |
IL177087A0 (en) | 2006-12-10 |
MXPA06010785A (es) | 2007-03-28 |
IL177087A (en) | 2011-11-30 |
CA2557791A1 (en) | 2005-10-06 |
NO20064874L (no) | 2006-12-19 |
NZ549838A (en) | 2010-04-30 |
ZA200607603B (en) | 2007-05-30 |
WO2005092336A1 (ja) | 2005-10-06 |
US20120003311A9 (en) | 2012-01-05 |
US20070110806A1 (en) | 2007-05-17 |
TW200602085A (en) | 2006-01-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2557791C (en) | Controlled-release pharmaceutical composition and method for producing the same | |
EP1715856B1 (en) | Atomoxetine formulations | |
US20050158383A1 (en) | Quetiapine formulations | |
US8221787B2 (en) | Pharmaceutical preparation for oral administration with controlled active ingredient release in the small intestine and method for its production | |
CA2552221A1 (en) | Donepezil formulations | |
US20070141137A1 (en) | Stable capsule preparation | |
EP1703898A2 (en) | Ziprasidone formulations | |
CA2539982A1 (en) | Pantoprazole multiparticulate formulations | |
RU2311906C2 (ru) | Композиция препарата замедленного высвобождения для высвобождения ингибитора секреции кислоты в желудке и способ ее получения | |
ZA200601838B (en) | Proton pump inhibitor formulations, and methods of preparing and using such formulations | |
KR20160021095A (ko) | 탐술로신 또는 이의 염의 약학 조성물 | |
AU2006247357B2 (en) | Morphine sulfate formulations | |
US20170119701A1 (en) | Metoprolol Sustained-Release Composition and Preparation Method Thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20130325 |